SFB 824: Imaging for Selection, Monitoring and Individualisation of Cancer Therapies

SFB 824：用于癌症治疗选择、监测和个体化的成像

• 批准号: 68647618
• 金额: --
• 依托单位: Ludwig-Maximilians-Universität München (LMU)
• 依托单位国家: 德国
• 项目类别: Collaborative Research Centres
• 财政年份: 2009
• 资助国家: 德国
• 起止时间: 2008-12-31 至 2020-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/68647618?language=en
• 关键词: SFB; 824; Imaging; Selection; Monitoring

The Collaborative Research Centre 824 (SFB 824, http://www.sfb824.de) constitutes a consortium of researchers from natural sciences, biology and clinical sciences, located at both Munich Universities – Technical University of Munich (TUM) and Ludwig Maximilian University (LMU) – as well as at the Helmholtz-Zentrum Munich (HMGU). The SFB 824 was first funded in July 2008 and is now in its 7th funding year. The overriding aim of this interdisciplinary research platform is to develop, validate, translate and ultimately apply cutting-edge imaging methods, which improve, substitute or even create new imaging approaches for early diagnosis, personalized therapeutic stratification and for monitoring of therapy effects in patients with cancer. In recent years, major advances in the molecular characterization of cancer have raised hopes for new molecularly tailored therapeutic strategies in the fight against deadly diseases. However, despite impressive success in preclinical models, clinical response to promising new agents and treatment modalities has been heterogeneous. The need for technologies to identify subgroups of patients likely to benefit from selected therapies targeting specific pathways or biological modalities and to guide and monitor treatment strategies is well recognized and absolutely fundamental for the worldwide advertised concept of precision medicine. Focus of SFB 824 is to meet this challenge by developing and validating new imaging strategies in preclinical tumor models aiming at fast translation into clinical settings. The current SFB 824 application consists of 19 individual projects, which are embedded in three interconnected research packages concentrating on (1) the introduction of new imaging methodology and imaging biomarkers, (2) the preclinical and clinical validation of identified molecular imaging targets and (3) the application of imaging modalities for monitoring effects of cancer therapeutics. SFB 824 is part of the core research strategy of TUM focusing on bioengineering as developmental platform for interdisciplinary research resulting in innovative diagnostic and therapeutic methods and their translation into clinical application. To this end, the consortium will also be integrated into the new Central Institute for Translational Cancer Research (TranslaTUM), a new research building providing an interdisciplinary research environment.

824合作研究中心（SFB 824，http://www.sfb824.de）由来自自然科学、生物学和临床科学的研究人员组成，位于慕尼黑两所大学-慕尼黑工业大学（TUM）和路德维希马克西米利安大学（LMU）-以及慕尼黑亥姆霍兹中心（HMGU）。SFB 824于2008年7月首次获得资助，目前已进入第七个资助年度。这个跨学科研究平台的首要目标是开发，验证，翻译并最终应用尖端成像方法，这些方法可以改善，替代甚至创造新的成像方法，用于早期诊断，个性化治疗分层和监测癌症患者的治疗效果。近年来，癌症分子表征的重大进展为在与致命疾病的斗争中新的分子定制治疗策略带来了希望。然而，尽管在临床前模型中取得了令人印象深刻的成功，但对有前途的新药物和治疗方式的临床反应是不均匀的。需要技术来确定可能受益于针对特定途径或生物模式的选定疗法的患者亚组，并指导和监测治疗策略，这是众所周知的，对于全球宣传的精准医学概念绝对至关重要。SFB 824的重点是通过在临床前肿瘤模型中开发和验证新的成像策略来应对这一挑战，旨在快速转化为临床环境。目前的SFB 824应用程序包括19个单独的项目，这些项目嵌入在三个相互关联的研究包中，集中于（1）引入新的成像方法和成像生物标志物，（2）已识别分子成像靶点的临床前和临床验证，以及（3）应用成像模式监测癌症治疗效果。SFB 824是TUM核心研究战略的一部分，专注于生物工程作为跨学科研究的发展平台，从而产生创新的诊断和治疗方法及其转化为临床应用。为此，该联盟还将被整合到新的转化癌症研究中心（Translatum），这是一个提供跨学科研究环境的新研究大楼。